Effects of bupropion sustained release on task-related EEG alpha activity in smokers: Individual differences in drug response.
The mechanisms underlying bupropion's efficacy as an antidepressant and a smoking cessation aid are far from being fully characterized. The present study is the first to examine the effects of bupropion on visuospatial task-related parietal EEG alpha power asymmetry-an asymmetry that has previously been found to be associated with severity of depressive symptoms (i.e., the more depressive symptoms, the greater alpha power in the right vs. left parietal area [Henriques & Davidson, 1997; Rabe, Debener, Brocke, & Beauducel, 2005]). Participants, all of whom were smokers and none of whom were clinically depressed, were randomly assigned to the Placebo group (n = 79) or Bupropion group (n = 31) in a double-blind study. EEG during the performance of the visuospatial task was collected before and after 14 days on placebo or bupropion sustained-release capsules. Relative to the Placebo group, the Bupropion group (especially, the Bupropion subgroup who had a positive right versus left parietal alpha power asymmetry at pretreatment) had a reduction in the parietal alpha asymmetry (driven largely by a decrease in right parietal alpha power). These findings support the hypothesis that bupropion can induce changes in parietal EEG asymmetry that have been shown in previous literature to be associated with a reduction in depressive states and traits. (PsycINFO Database Record
Department of Psychology, Southern Illinois University Carbondale.
Jian
J
Zhu
Department of Psychology, Southern Illinois University Carbondale.
Ryan P
RP
Coppens
Department of Psychology, Southern Illinois University Carbondale.
Norka E
NE
Rabinovich
Department of Psychology, Southern Illinois University Carbondale.
David G
DG
Gilbert
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000494:pharmacology*; D016642:Bupropion / Q000008:administration & dosage / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D012907:Smoking / Q000523:psychology*; D016540:Smoking Cessation / Q000379:methods; D014796:Visual Perception; D055815:Young Adult
D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D016642:Bupropion